A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibits the clearance of low-density lipoprotein (LDL) cholesterol (LDL-C) from plasma by directly binding with the LDL receptor (LDLR) and sending the receptor for lysosomal degradation. As the interaction promotes elevated plasma LDL-C levels,...

Full description

Bibliographic Details
Main Authors: Alexandra K. Suchowerska, Geurt Stokman, James T. Palmer, Phillip A. Coghlan, Elsbet J. Pieterman, Nanda Keijzer, Gilles Lambert, Kevin Chemello, Ali K. Jaafar, Jasneet Parmar, Liping Yan, Yingtao Tong, Lin Mu, Hans M.G. Princen, James Bonnar, Benny J. Evison
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:Journal of Lipid Research
Subjects:
PCSK9
cardiovascular disease
hypercholesterolemia
small-molecule
lipoproteins
apolipoproteins
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227522001262

Internet

http://www.sciencedirect.com/science/article/pii/S0022227522001262

Similar Items